Hope Tribune

Dystrophic Epidermolysis Bullosa Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) – Estimates DelveInsight | Eloxx, Krystal Biotech, Phoenicis, Quoin, RegeneRx

 Breaking News
  • No posts were found

Dystrophic Epidermolysis Bullosa Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) – Estimates DelveInsight | Eloxx, Krystal Biotech, Phoenicis, Quoin, RegeneRx

September 06
01:28 2023
Dystrophic Epidermolysis Bullosa Market to Expand at a Significant Growth Rate During the Forecast Period (2023-32) -  Estimates DelveInsight | Eloxx, Krystal Biotech, Phoenicis, Quoin, RegeneRx
Delveinsight Business Research LLP
As per DelveInsight, in the seven major markets, the Dystrophic Epidermolysis Bullosa market size was found to be USD 500 Million in 2021. The Dystrophic Epidermolysis Bullosa Market is set to register immense growth in the coming years owing to the launch of the drug candidates that are under investigation and the rise in the number of cases of Dystrophic Epidermolysis Bullosa in the 7MM.

Companies across the globe are working toward the development of therapeutic drugs for the treatment of Dystrophic Epidermolysis Bullosa with a considerable amount of success over the years. Key players, such as Amryt Pharma, RegeneRx Biopharmaceuticals, Gtree Pharmaceuticals, etc., are actively working in the therapeutics market. FCX-007, RGN-137, AP-101/ AP-103, and B-VEC are some of the emerging therapies, that are anticipated to change the Dystrophic Epidermolysis Bullosa treatment scenario and the market dynamics after their approval and successful launch in the market.

DelveInsight’s “Dystrophic Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Dystrophic Epidermolysis Bullosa market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Dystrophic Epidermolysis Bullosa drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Dystrophic Epidermolysis Bullosa treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Dystrophic Epidermolysis Bullosa: An Overview

Epidermolysis Bullosa (EB) is a group of skin diseases that cause various degrees of skin and mucous membrane fragility. The skin becomes fragile when proteins essential for skin integrity are absent, reduced, or abnormal. It is characterized by blister formation in response to mechanical trauma.

To date, there is no treatment or cure for EB. EB is generally caused by mutations involving at least 18 genes encoding structural proteins within keratin intermediate filaments, focal adhesions, desmosome cell junctions, and hemidesmosome attachment complexes. There are various types and subtypes of EB. As per the most recent classification, EB is broadly classified into: EB Simplex (EBS), Junctional EB (JEB), Dystrophic EB (DEB), and Kindler syndrome.

DEB is one of the major forms of EB. It is caused by mutations in the COL7A1 gene and may be inherited in an autosomal dominant or autosomal recessive manner. All DEB subtypes are caused by mutations in COL7A1, which encodes type VII collagen, a major component of anchoring fibrils.

Dystrophic Epidermolysis Bullosa Market Key Facts

  • Assessments as per DelveInsight’s analysts show that the total diagnosed prevalent cases of Epidermolysis Bullosa in 7MM were nearly 41,000 in 2021.

  • In 2021, the US accounted for nearly 26,000 total diagnosed prevalent cases of Epidermolysis Bullosa, which was the highest count among 7MM.

  • In 2021, there were ~4,200 diagnosed prevalent cases of DEB in the EU5. Germany had the highest diagnosed prevalent population of DEB, followed by the UK. On the other hand, France had the lowest diagnosed prevalent population in 2021.

  • Japan had nearly 1,100 diagnosed prevalent cases of DEB in 2021. Out of these cases, 61.1% cases were of RDEB type.

  • Based on the assessment, it can be concluded that there is no significant difference in the occurrence of Dystrophic Epidermolysis Bullosa (DEB) among the male and female populations.

  • Many companies are developing possible treatments for Dystrophic Epidermolysis Bullosa with continuous efforts in research and development. Castle Creek Biosciences (FCX-007), Amryt Pharma (Oleogel-S10), Krystal Biotech (Beremagene Geperpavec), Abeona Therapeutics (EB-101), and Phoenix Tissue Repair (PTR-01) are key players working on potential therapies like gene therapy, symptomatic relief therapy, and disease-modifying therapies. Currently, these therapies are in the mid and late phases of development and are expected to enter the market during the forecast period.

Dystrophic Epidermolysis Bullosa Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Dystrophic Epidermolysis Bullosa pipeline therapies. It also thoroughly assesses the Dystrophic Epidermolysis Bullosa market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Dystrophic Epidermolysis Bullosa drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Dystrophic Epidermolysis Bullosa Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Dystrophic Epidermolysis Bullosa epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Dystrophic Epidermolysis Bullosa epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Dystrophic Epidermolysis Bullosa Epidemiology, Segmented as –

  • Total Diagnosed Prevalent Population of Epidermolysis Bullosa (EB) in the 7MM (2019–2032)

  • Total Diagnosed Prevalent Population of Dystrophic Epidermolysis Bullosa (DEB) in the 7MM (2019–2032)

  • Subtype-specific Diagnosed Prevalent Population of Dystrophic Epidermolysis Bullosa (DEB) (e.g. (RDEB, DDEB) in the 7MM (2019–2032)

Dystrophic Epidermolysis Bullosa Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Dystrophic Epidermolysis Bullosa market or expected to be launched during the study period. The analysis covers the Dystrophic Epidermolysis Bullosa market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Dystrophic Epidermolysis Bullosa drugs based on their sale and market share.

The report also covers the Dystrophic Epidermolysis Bullosa pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Dystrophic Epidermolysis Bullosa companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Dystrophic Epidermolysis Bullosa Market Will Evolve and Grow by 2032 @ 

https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market

Dystrophic Epidermolysis Bullosa Therapeutics Analysis

Several major pharma and biotech giants are developing therapies for Dystrophic Epidermolysis Bullosa. Currently, Castle Creek Biosciences is leading the therapeutics market with its Dystrophic Epidermolysis Bullosa drug candidates in the most advanced stage of clinical development.

Dystrophic Epidermolysis Bullosa Companies Actively Working in the Therapeutics Market Include

  • Castle Creek Biosciences

  • Eloxx Pharmaceuticals

  • InMed Pharmaceuticals

  • Krystal Biotech

  • Phoenicis Therapeutics

  • Phoenix Tissue Repair

  • Quoin Pharmaceuticals

  • RegeneRx Biopharmaceuticals

  • Relief Therapeutics

  • RHEACELL GmbH & Co. KG

And many others

Emerging and Marketed Dystrophic Epidermolysis Bullosa Therapies Covered in the Report Include:

  • Beremagene geperpavec: Krystal Biotech

  • D-Fi (dabocemagene autoficel, formerly known as FCX-007): Castle Creek Pharmaceutical

  • Oleogel-S10 (AP-101): Amryt Pharma

  • PTR-01: Phoenix Tissue Repair

  • RGN-137 (also known as GBT-101): RegeneRx Biopharmaceuticals/Gtree Pharmaceuticals

And many more

The Report Covers an In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Dystrophic Epidermolysis Bullosa Competitive Intelligence Analysis

4. Dystrophic Epidermolysis Bullosa Market Overview at a Glance

5. Dystrophic Epidermolysis Bullosa Disease Background and Overview

6. Dystrophic Epidermolysis Bullosa Patient Journey

7. Dystrophic Epidermolysis Bullosa Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Dystrophic Epidermolysis Bullosa Treatment Algorithm, Current Treatment, and Medical Practices

9. Dystrophic Epidermolysis Bullosa Unmet Needs

10. Key Endpoints of Dystrophic Epidermolysis Bullosa Treatment

11. Dystrophic Epidermolysis Bullosa Marketed Therapies

12. Dystrophic Epidermolysis Bullosa Emerging Drugs and Latest Therapeutic Advances

13. Dystrophic Epidermolysis Bullosa Seven Major Market Analysis

14. Attribute Analysis

15. Dystrophic Epidermolysis Bullosa Market Outlook (In US, EU5, and Japan)

16. Dystrophic Epidermolysis Bullosa Companies Active in the Market

17. Dystrophic Epidermolysis Bullosa Access and Reimbursement Overview

18. KOL Views on the Dystrophic Epidermolysis Bullosa Market

19. Dystrophic Epidermolysis Bullosa Market Drivers

20. Dystrophic Epidermolysis Bullosa Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @

https://www.delveinsight.com/sample-request/dystrophic-epidermolysis-bullosa-market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight 

Failed Back Surgery Syndrome Market

“Failed Back Surgery Syndrome Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Failed Back Surgery Syndrome market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Failed Back Surgery Syndrome market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices

Categories